US5506242A
(en)
*
|
1993-01-06 |
1996-04-09 |
Ciba-Geigy Corporation |
Arylsufonamido-substituted hydroxamic acids
|
US5646167A
(en)
*
|
1993-01-06 |
1997-07-08 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamix acids
|
US5552419A
(en)
*
|
1993-01-06 |
1996-09-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
GB9411598D0
(en)
*
|
1994-06-09 |
1994-08-03 |
Hoffmann La Roche |
Hydroxamic acid derivatives
|
AU690703B2
(en)
*
|
1994-06-22 |
1998-04-30 |
British Biotech Pharmaceuticals Limited |
Metalloproteinase inhibitors
|
US5817822A
(en)
*
|
1994-06-24 |
1998-10-06 |
Novartis Corporation |
Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
|
US5519060A
(en)
*
|
1995-01-17 |
1996-05-21 |
The Trustees Of The University Of Pennsylvania |
Sulfonamide-based compositions and methods
|
US5863949A
(en)
*
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
PT821671E
(pt)
*
|
1995-04-20 |
2001-04-30 |
Pfizer |
Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
|
EP0832875B1
(en)
|
1995-04-25 |
2004-06-30 |
Daiichi Fine Chemical Co., Ltd. |
Highly water-soluble metalloproteinase inhibitor
|
WO1996036611A1
(en)
*
|
1995-05-19 |
1996-11-21 |
Chiroscience Limited |
3,4-disubstituted-phenylsulphonamides and their therapeutic use
|
US6124333A
(en)
*
|
1995-06-22 |
2000-09-26 |
British Biotech Pharmaceuticals Limited |
Metalloproteinase inhibitors
|
KR980009238A
(ko)
*
|
1995-07-28 |
1998-04-30 |
우에노 도시오 |
설포닐아미노산 유도체
|
ATE226936T1
(de)
*
|
1995-08-08 |
2002-11-15 |
Ono Pharmaceutical Co |
Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
|
BR9609883A
(pt)
*
|
1995-08-08 |
1999-03-23 |
Fibrogen Inc |
Composto tendo efeito inibidor em proteinase c composição farmacéutica e processo para tratar doenças relacionadas com a produção inapropriada ou desregulada de colágeno
|
TR199800849T2
(xx)
*
|
1995-11-13 |
1998-07-21 |
Hoechst Aktiengesellschaft |
Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
|
ATE225779T1
(de)
|
1995-11-17 |
2002-10-15 |
Warner Lambert Co |
Sulfonamidinhibitoren von matrix metalloproteinasen
|
AU1328197A
(en)
|
1995-12-01 |
1997-06-19 |
Synaptic Pharmaceutical Corporation |
Aryl sulfonamide and sulfamide derivatives and uses thereof
|
US5753653A
(en)
|
1995-12-08 |
1998-05-19 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
ES2233275T3
(es)
*
|
1995-12-08 |
2005-06-16 |
Agouron Pharmaceuticals, Inc. |
Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
|
US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
TW453995B
(en)
*
|
1995-12-15 |
2001-09-11 |
Novartis Ag |
Certain alpha-substituted arylsulfonamido acetohydroxamic acids
|
DE69624081T2
(de)
*
|
1995-12-20 |
2003-06-12 |
Hoffmann La Roche |
Matrix-metalloprotease Inhibitoren
|
DE69728375T2
(de)
*
|
1996-01-02 |
2005-02-10 |
Aventis Pharmaceuticals Inc. |
Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
|
JP3628335B2
(ja)
|
1996-01-23 |
2005-03-09 |
塩野義製薬株式会社 |
スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤
|
US6919375B1
(en)
|
1996-01-23 |
2005-07-19 |
Shionogi & Co., Ltd. |
Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
|
US5994351A
(en)
*
|
1998-07-27 |
1999-11-30 |
Pfizer Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
FR2748026B1
(fr)
*
|
1996-04-26 |
1998-06-05 |
Adir |
Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US5854275A
(en)
*
|
1996-05-16 |
1998-12-29 |
Pfizer Inc. |
Cyclic imide derivatives
|
AU2792097A
(en)
*
|
1996-05-24 |
1998-01-05 |
Ono Pharmaceutical Co. Ltd. |
Phenylsulfonamide derivatives
|
EP0818442A3
(en)
*
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
KR20000067964A
(ko)
*
|
1996-07-22 |
2000-11-25 |
죤 에이치. 뷰센 |
티올 술폰아미드 메탈로프로테아제 저해제
|
PL331895A1
(en)
*
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
IL128661A
(en)
*
|
1996-08-28 |
2001-10-31 |
Procter & Gamble |
Teleprotease inhibitors 1, 3 - diethocycles and pharmaceutical preparations containing them
|
CN1228773A
(zh)
*
|
1996-08-28 |
1999-09-15 |
普罗克特和甘保尔公司 |
杂环金属蛋白酶抑制剂
|
PL331854A1
(en)
*
|
1996-08-28 |
1999-08-16 |
Procter & Gamble |
Phosphinamides as inhibitors of metaloprotease matrix
|
NZ334257A
(en)
*
|
1996-08-28 |
2000-11-24 |
Procter & Gamble |
Spirocyclic metalloprotease inhibitors
|
DK0927161T3
(da)
*
|
1996-08-28 |
2003-02-17 |
Procter & Gamble |
Substitueret cyklisk amin-metalloproteaseinhibitorer
|
BR9712792A
(pt)
*
|
1996-08-28 |
1999-12-14 |
Procter & Gamble |
Inibidores de metaloprotease bidentada.
|
EP0923561B1
(en)
*
|
1996-08-28 |
2002-10-23 |
The Procter & Gamble Company |
Heterocyclic metalloprotease inhibitors
|
US6872742B2
(en)
*
|
1996-08-28 |
2005-03-29 |
The Procter & Gamble Company |
Substituted cyclic amine metalloprotease inhibitors
|
KR20000068414A
(ko)
*
|
1996-09-04 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도
|
AU736347B2
(en)
|
1996-09-04 |
2001-07-26 |
Warner-Lambert Company |
Compounds for and a method of inhibiting matrix metalloproteinases
|
US6624177B1
(en)
|
1996-09-04 |
2003-09-23 |
Warner-Lambert Company |
Matrix metalloproteinase inhibitors and their therapeutic uses
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
AU743901B2
(en)
*
|
1996-10-16 |
2002-02-07 |
Wyeth Holdings Corporation |
Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
PT934259E
(pt)
*
|
1996-10-16 |
2003-01-31 |
American Cyanamid Co |
Acidos beta-sulfonamido hidroxamicos como inibidores de metaloproteinases de matriz e de tace
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
KR20000049197A
(ko)
*
|
1996-10-16 |
2000-07-25 |
윌리암 에이취 캘넌, 에곤 이 버그 |
매트릭스 메탈로프로테이나제 및 종양 괴사 인자-α 전환 효소억제제로서의 오르토-설폰아미도 헤테로아릴 하이드록삼산의 제조 및 용도
|
BR9712525A
(pt)
*
|
1996-10-16 |
1999-10-19 |
American Cyanamid Co |
O preparo e uso de ácidos orto-sulfonamido aril hidroxmicos como inibidores da metaloproteinase matricial e da tace
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
ATE212619T1
(de)
*
|
1996-10-22 |
2002-02-15 |
Upjohn Co |
Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
WO1998018754A1
(en)
|
1996-10-28 |
1998-05-07 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
KR20000057595A
(ko)
|
1996-12-17 |
2000-09-25 |
후지야마 아키라 |
Mmp 또는 tnf의 억제제로서 피페라진 화합물
|
EP1366765A1
(en)
*
|
1996-12-17 |
2003-12-03 |
Warner-Lambert Company Llc |
Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
|
NZ334925A
(en)
*
|
1996-12-17 |
2001-06-29 |
Warner Lambert Co |
Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing using 2-(4'-bromobiphenyl-4-sulfonylamino)-3-methyl-butyric acid and 4-(4'-chloro-biphenyl-4-yl)-4-hydroxyimino-butyric acid
|
UA59384C2
(uk)
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
CA2277100C
(en)
*
|
1997-01-06 |
2005-11-22 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
AU720615B2
(en)
*
|
1997-01-17 |
2000-06-08 |
Pharmacia & Upjohn Company |
Bis-sulfonomides hydroxamic acids as MMP inhibitors
|
WO1998032734A1
(en)
|
1997-01-22 |
1998-07-30 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
SUBSTITUTED β-THIOCARBOXYLIC ACIDS
|
ZA98376B
(en)
*
|
1997-01-23 |
1998-07-23 |
Hoffmann La Roche |
Sulfamide-metalloprotease inhibitors
|
WO1998032748A1
(en)
*
|
1997-01-23 |
1998-07-30 |
F. Hoffmann-La Roche Ag |
Sulfamide-metalloprotease inhibitors
|
US6376506B1
(en)
|
1997-01-23 |
2002-04-23 |
Syntex (U.S.A.) Llc |
Sulfamide-metalloprotease inhibitors
|
AU5577498A
(en)
*
|
1997-01-31 |
1998-08-25 |
Shionogi & Co., Ltd. |
Compounds having metalloprotease inhibitory activity
|
CN1113862C
(zh)
|
1997-02-03 |
2003-07-09 |
辉瑞产品公司 |
芳基磺酰氨基异羟肟酸衍生物
|
NZ336836A
(en)
|
1997-02-11 |
2001-02-23 |
Pfizer |
Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
|
US6172057B1
(en)
|
1997-02-27 |
2001-01-09 |
American Cyanamid Company |
N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
|
GEP20022626B
(en)
*
|
1997-02-27 |
2002-02-25 |
American Cyanamid Company Us |
N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors
|
US6197791B1
(en)
|
1997-02-27 |
2001-03-06 |
American Cyanamid Company |
N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
|
US6696449B2
(en)
|
1997-03-04 |
2004-02-24 |
Pharmacia Corporation |
Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
|
DE69828783T2
(de)
|
1997-03-04 |
2006-01-12 |
Pharmacia Corp. |
Hydroxamsäure-sulfonamid-derivate mit amidiertem aromatischen ring
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
EA199900792A1
(ru)
|
1997-03-04 |
2000-04-24 |
Монсанто Компани |
Сульфонильные двухвалентные арильные или гетероарильные соединения гидроксамовой кислоты
|
US6794511B2
(en)
|
1997-03-04 |
2004-09-21 |
G. D. Searle |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
GB9706255D0
(en)
*
|
1997-03-26 |
1997-05-14 |
Smithkline Beecham Plc |
Novel compounds
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US5756545A
(en)
*
|
1997-04-21 |
1998-05-26 |
Warner-Lambert Company |
Biphenysulfonamide matrix metal alloproteinase inhibitors
|
WO1998050348A1
(en)
*
|
1997-05-09 |
1998-11-12 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
DE19719621A1
(de)
|
1997-05-09 |
1998-11-12 |
Hoechst Ag |
Sulfonylaminocarbonsäuren
|
DE59802394D1
(de)
|
1997-05-09 |
2002-01-24 |
Hoechst Ag |
Substituierte Diaminocarbonsäuren
|
DE19719817A1
(de)
*
|
1997-05-13 |
1998-11-19 |
Hoechst Ag |
Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
|
US6300514B1
(en)
|
1997-06-25 |
2001-10-09 |
Ono Pharmaceutical Co., Ltd. |
Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
|
WO1999006340A2
(en)
|
1997-07-31 |
1999-02-11 |
The Procter & Gamble Company |
Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
|
ATE263147T1
(de)
*
|
1997-08-08 |
2004-04-15 |
Pfizer Prod Inc |
Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
|
SI1003720T1
(en)
*
|
1997-08-08 |
2004-06-30 |
Pfizer Products Inc. |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
US6130220A
(en)
*
|
1997-10-16 |
2000-10-10 |
Syntex (Usa) Inc. |
Sulfamide-metalloprotease inhibitors
|
WO1999025687A1
(en)
|
1997-11-14 |
1999-05-27 |
G.D. Searle & Co. |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
US20010039287A1
(en)
|
1997-11-14 |
2001-11-08 |
Thomas E Barta |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
US6750228B1
(en)
|
1997-11-14 |
2004-06-15 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
GB9725782D0
(en)
*
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US6107291A
(en)
*
|
1997-12-19 |
2000-08-22 |
Amgen Inc. |
Azepine or larger medium ring derivatives and methods of use
|
US6335329B1
(en)
|
1997-12-19 |
2002-01-01 |
Amgen Inc. |
Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
|
GB9801690D0
(en)
*
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
KR20010041089A
(ko)
*
|
1998-02-19 |
2001-05-15 |
윌리암 에이취 캘넌, 에곤 이 버그 |
매트릭스 메탈로프로테이나제 억제제로서의n-하이드록시-2-(알킬, 아릴, 또는 헤테로아릴 설파닐,설피닐 또는 설포닐)-3-치환된 알킬, 아릴 또는헤테로아릴아미드
|
BR9908564A
(pt)
|
1998-03-12 |
2000-12-05 |
Procter & Gamble |
Artigo absorvente e processo para reduzir a atividade de enzimas proteolìticas de uma protéase fecal presente no mesmo
|
US6703536B2
(en)
|
1998-03-12 |
2004-03-09 |
The Procter & Gamble Company |
Disposable absorbent article having a skin care composition containing an enzyme inhibitor
|
AU756248B2
(en)
*
|
1998-04-03 |
2003-01-09 |
Sankyo Company Limited |
Sulfonamide derivatives
|
PA8469501A1
(es)
*
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
US6329418B1
(en)
|
1998-04-14 |
2001-12-11 |
The Procter & Gamble Company |
Substituted pyrrolidine hydroxamate metalloprotease inhibitors
|
ES2187171T3
(es)
|
1998-07-16 |
2003-05-16 |
Aventis Pharma Gmbh |
Derivados de acidos fosfinico y fosfonico en calidad de medicamentos.
|
HRP990246A2
(en)
|
1998-08-07 |
2000-06-30 |
Du Pont Pharm Co |
Succinoylamino benzodiazepines as inhibitors of a beta protein production
|
NZ525513A
(en)
|
1998-08-07 |
2004-09-24 |
Pont Pharmaceuticals Du |
Succinoylamino lactams as inhibitors of Abeta protein production
|
FR2782080B1
(fr)
*
|
1998-08-10 |
2001-01-05 |
Adir |
Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6509337B1
(en)
|
1998-09-17 |
2003-01-21 |
Pfizer Inc. |
Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
|
DE19851184A1
(de)
*
|
1998-11-06 |
2000-05-11 |
Aventis Pharma Gmbh |
N-Arylsulfonyl-aminosäure-omega-amide
|
CA2346099A1
(en)
*
|
1998-11-12 |
2000-05-18 |
Dupont Pharmaceuticals Company |
Use of radioligands to screen inhibitors of amyloid-beta peptide production
|
US6737038B1
(en)
|
1998-11-12 |
2004-05-18 |
Bristol-Myers Squibb Company |
Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
|
US6492394B1
(en)
|
1998-12-22 |
2002-12-10 |
Syntex (U.S.A.) Llc |
Sulfonamide hydroxamates
|
YU44901A
(sh)
*
|
1998-12-22 |
2003-12-31 |
F. Hofmann-La Roche Ag. |
Sulfonamid hidroksamati
|
US6946473B2
(en)
*
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
US6544984B1
(en)
|
1999-01-27 |
2003-04-08 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
BR0007784A
(pt)
|
1999-01-27 |
2002-02-05 |
American Cyanamid Co |
Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
AR022423A1
(es)
*
|
1999-01-27 |
2002-09-04 |
American Cyanamid Co |
Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
|
US6753337B2
(en)
*
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
SK11352001A3
(sk)
|
1999-02-08 |
2002-09-10 |
G. D. Searle & Co. |
Metaloproteázový inhibítor kyselina sulfamátohydroxámová
|
US6506936B1
(en)
|
1999-02-25 |
2003-01-14 |
Fibrogen, Inc. |
N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
|
KR20010102485A
(ko)
|
1999-03-03 |
2001-11-15 |
데이비드 엠 모이어 |
디헤테로-치환된 메탈로프로테아제 저해제
|
MXPA01008855A
(es)
|
1999-03-03 |
2002-07-02 |
Procter & Gamble |
Inhibidores de metaloproteasa que contienen alquenilo y alquinilo.
|
ES2200783T3
(es)
*
|
1999-03-31 |
2004-03-16 |
Pfizer Products Inc. |
Acidos dioxociclopentil hidroxamicos.
|
AU4249700A
(en)
*
|
1999-04-19 |
2000-11-02 |
Sumitomo Pharmaceuticals Company, Limited |
Hydroxamic acid derivative
|
HN2000000052A
(es)
*
|
1999-05-28 |
2001-02-02 |
Pfizer Prod Inc |
Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
|
ATE254119T1
(de)
*
|
1999-05-28 |
2003-11-15 |
Pfizer Prod Inc |
3-(arylsulfonylamino)-tetrahydropyran-3- carbonsäure hydroxamide
|
US6511993B1
(en)
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
GB9912961D0
(en)
*
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
GB9918684D0
(en)
*
|
1999-08-09 |
1999-10-13 |
Novartis Ag |
Organic compounds
|
EP1081137A1
(en)
|
1999-08-12 |
2001-03-07 |
Pfizer Products Inc. |
Selective inhibitors of aggrecanase in osteoarthritis treatment
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
AU2001233965A1
(en)
*
|
2000-02-24 |
2001-09-03 |
Smithkline Beecham Plc |
Novel cd23 inhibitors
|
US6465508B1
(en)
|
2000-02-25 |
2002-10-15 |
Wyeth |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
|
US6458822B2
(en)
|
2000-03-13 |
2002-10-01 |
Pfizer Inc. |
2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
|
US6455587B1
(en)
*
|
2000-03-15 |
2002-09-24 |
Pharmacor Inc. |
Amino acid derivatives as HIV aspartyl protease inhibitors
|
BR0109354A
(pt)
*
|
2000-03-21 |
2003-04-15 |
Procter & Gamble |
Inibidores de metaloproteases os quais contêm cadeias laterais carbocìclicas
|
IL151250A0
(en)
|
2000-03-21 |
2003-04-10 |
Procter & Gamble |
Difluorobutyric acid metalloprotease inhibitors
|
WO2001070720A2
(en)
*
|
2000-03-21 |
2001-09-27 |
The Procter & Gamble Company |
Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
|
BR0109328A
(pt)
*
|
2000-03-21 |
2003-06-10 |
Procter & Gamble |
Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
|
MXPA02009312A
(es)
*
|
2000-03-21 |
2003-03-12 |
Procter & Gamble |
Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas.
|
JP4074043B2
(ja)
|
2000-03-27 |
2008-04-09 |
株式会社資生堂 |
皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
|
EP1138680A1
(en)
|
2000-03-29 |
2001-10-04 |
Pfizer Products Inc. |
Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
|
US6495358B1
(en)
|
2000-04-19 |
2002-12-17 |
Wichita State University |
Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
|
US6713477B1
(en)
|
2000-04-19 |
2004-03-30 |
Sumitomo Pharmaceuticals Company, Limited |
Hydroxamic acid derivatives
|
US6683093B2
(en)
|
2000-05-12 |
2004-01-27 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acids and their use as protease inhibitors
|
JP2002047125A
(ja)
*
|
2000-05-26 |
2002-02-12 |
Shiseido Co Ltd |
皮脂分泌抑制用皮膚外用剤
|
BR0106717A
(pt)
|
2000-06-01 |
2002-04-16 |
Bristol Myers Squibb Pharma Co |
Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
WO2002047696A1
(de)
|
2000-12-16 |
2002-06-20 |
Aventis Pharma Deutschland Gmbh |
Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
|
PE20020801A1
(es)
|
2001-01-05 |
2002-09-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
FR2819252A1
(fr)
*
|
2001-01-11 |
2002-07-12 |
Servier Lab |
Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
FR2819253B1
(fr)
*
|
2001-01-11 |
2004-12-03 |
Servier Lab |
Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
GB0103303D0
(en)
*
|
2001-02-09 |
2001-03-28 |
Novartis Ag |
Organic compounds
|
JP4228700B2
(ja)
|
2001-04-10 |
2009-02-25 |
日本新薬株式会社 |
慢性関節リウマチの治療剤
|
BR0209525A
(pt)
|
2001-05-11 |
2004-03-09 |
Pharmacia Corp |
Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de protease
|
CA2449999C
(en)
*
|
2001-06-11 |
2012-07-31 |
Shire Biochem Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
BR0213736A
(pt)
*
|
2001-11-01 |
2004-10-19 |
Wyeth Corp |
ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US6933298B2
(en)
|
2001-12-08 |
2005-08-23 |
Aventis Pharma Deutschland Gmbh |
Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
US6716853B2
(en)
|
2002-03-02 |
2004-04-06 |
Aventis Pharma Deutschland Gmbh |
Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
|
AR038971A1
(es)
|
2002-03-13 |
2005-02-02 |
Array Biopharma Inc |
Derivados de bencimidazol n3 alquilado como inhibidores de mek
|
US7119203B2
(en)
|
2002-04-25 |
2006-10-10 |
Pharmacia Corporation |
Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
|
MXPA04008563A
(es)
|
2002-04-26 |
2004-12-06 |
Pfizer Prod Inc |
Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
|
WO2003090751A1
(en)
|
2002-04-26 |
2003-11-06 |
Pfizer Products Inc. |
Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
|
NI200300045A
(es)
|
2002-04-26 |
2005-07-08 |
Pfizer Prod Inc |
Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
|
MXPA04010545A
(es)
|
2002-04-26 |
2005-01-25 |
Pfizer Prod Inc |
Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida.
|
WO2003104224A1
(en)
|
2002-06-10 |
2003-12-18 |
Pfizer Inc. |
Metabolites of prinomastat and their sythesis
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
WO2004012737A1
(en)
*
|
2002-07-29 |
2004-02-12 |
Novartis Ag |
Use or arylsulfonamido-substituted hydroxamid acid matrix metalloproteinase inhibitors for the treatment or prevention of toxemia
|
US7166609B2
(en)
|
2002-11-02 |
2007-01-23 |
Sanofi-Aventis Deutschland Gmbh |
Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
|
RS20050430A
(en)
|
2002-12-19 |
2007-08-03 |
Pfizer Inc., |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
|
WO2005021489A2
(en)
*
|
2002-12-23 |
2005-03-10 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
|
DE10300015A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
|
US6878404B2
(en)
*
|
2003-02-06 |
2005-04-12 |
Guardian Industries Corp. |
Method of depositing DLC on substrate
|
JP2006517960A
(ja)
*
|
2003-02-18 |
2006-08-03 |
ファイザー インコーポレイテッド |
C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
|
BRPI0407827B8
(pt)
|
2003-02-26 |
2021-05-25 |
Sugen Inc |
compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
WO2005021554A1
(en)
|
2003-08-29 |
2005-03-10 |
Pfizer Inc. |
Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
DE10344936A1
(de)
*
|
2003-09-27 |
2005-04-21 |
Aventis Pharma Gmbh |
Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
|
PT2251327E
(pt)
|
2003-11-19 |
2014-03-04 |
Array Biopharma Inc |
Inibidores heterocíclicos de mek
|
WO2005051919A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
DE102004004974A1
(de)
|
2004-01-31 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
|
US7163942B2
(en)
|
2004-04-01 |
2007-01-16 |
Pfizer Inc. |
Sulfonamide compounds for the treatment of neurodegenerative disorders
|
WO2005108367A1
(en)
*
|
2004-05-03 |
2005-11-17 |
Envivo Pharmaceuticals, Inc. |
Compounds for treatment of neurodegenerative diseases
|
US20050277897A1
(en)
*
|
2004-06-14 |
2005-12-15 |
Ghannoum Ziad R |
Handpiece tip
|
CN101014365B
(zh)
|
2004-07-16 |
2011-04-13 |
辉瑞产品公司 |
使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
|
ITFI20040174A1
(it)
*
|
2004-08-03 |
2004-11-03 |
Protera S R L |
Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
|
PL1786785T3
(pl)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
CN102304086B
(zh)
|
2005-05-18 |
2013-12-04 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
JP5390184B2
(ja)
*
|
2005-06-06 |
2014-01-15 |
ファイブローゲン、インコーポレーテッド |
貧血の改良された治療方法
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
US7820664B2
(en)
|
2007-01-19 |
2010-10-26 |
Bayer Schering Pharma Ag |
Inhibitors of MEK
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
EP2012786B1
(en)
|
2006-04-18 |
2010-10-06 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
DK2041181T3
(da)
*
|
2006-06-08 |
2011-08-29 |
Helmholtz Zentrum Muenchen |
Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
|
JP2010513263A
(ja)
|
2006-12-15 |
2010-04-30 |
ファイザー・プロダクツ・インク |
ベンズイミダゾール誘導体
|
JP4782239B2
(ja)
|
2007-04-18 |
2011-09-28 |
ファイザー・プロダクツ・インク |
異常細胞増殖治療のためのスルホニルアミド誘導体
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
CA2694646C
(en)
|
2007-07-30 |
2017-09-05 |
Ardea Biosciences, Inc. |
Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
|
JP2011517313A
(ja)
|
2007-12-11 |
2011-06-02 |
ビアメト ファーマシューティカルズ,インク. |
金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
|
DK2222675T3
(da)
|
2007-12-19 |
2013-11-04 |
Genentech Inc |
5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
|
JP5710269B2
(ja)
|
2007-12-21 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
アザインドリジン類と使用方法
|
SG10201605472WA
(en)
|
2008-01-04 |
2016-09-29 |
Intellikine Llc |
Certain Chemical Entities, Compositions And Methods
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
US8895546B2
(en)
|
2009-03-27 |
2014-11-25 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
US20090258865A1
(en)
|
2008-03-28 |
2009-10-15 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
US8586748B2
(en)
*
|
2008-04-09 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10
|
KR20110039326A
(ko)
|
2008-07-08 |
2011-04-15 |
인텔리카인, 인크. |
키나제 억제제 및 사용 방법
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
NZ594177A
(en)
|
2009-02-05 |
2014-02-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
EP2393814A1
(en)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
CN106478496A
(zh)
|
2009-03-27 |
2017-03-08 |
阿迪生物科学公司 |
作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
|
EP2990051B1
(en)
|
2009-04-10 |
2016-10-26 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (mmp-1)
|
MX2011011428A
(es)
*
|
2009-05-01 |
2011-11-29 |
Raqualia Pharma Inc |
Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
|
EP2427195B1
(en)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
WO2011014726A1
(en)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
CA2771532C
(en)
|
2009-08-17 |
2021-03-23 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
ITTO20090648A1
(it)
*
|
2009-08-19 |
2011-02-20 |
Istituto Naz Per La Ricerca Sul Cancro |
Inibitori di adam17 atti a modulare il rilascio di alcam (cd166) solubile in cellule tumorali e loro uso nel trattamento terapeutico del carcinoma ovarico epiteliale (eoc)
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
ES2534358T3
(es)
|
2009-10-13 |
2015-04-21 |
Allomek Therapeutics, Llc |
Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
SG10201500895XA
(en)
|
2009-11-05 |
2015-04-29 |
Rhizen Pharmaceuticals Sa |
Chromen-4-one Derivatives As Kinase Modulators
|
AU2011215900A1
(en)
|
2010-02-10 |
2012-07-26 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
MX343383B
(es)
|
2010-02-12 |
2016-11-03 |
Pfizer Inc * |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
IT1401253B1
(it)
|
2010-04-23 |
2013-07-18 |
Uni Degli Studi Carlo Bo Urbino |
Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
|
CN103068824B
(zh)
|
2010-05-17 |
2017-09-08 |
印蔻真治疗公司 |
作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]***并[4,5‑b]吡啶化合物
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
EP2582727B8
(en)
|
2010-06-16 |
2017-04-19 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
US9056865B2
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2-derivatives as smoothened receptor modulators
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
US9353127B2
(en)
|
2011-02-15 |
2016-05-31 |
Immunogen, Inc. |
Methods of preparation of conjugates
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
US20140178368A1
(en)
|
2011-04-19 |
2014-06-26 |
Leslie Lynne SHARP |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
CA2833935C
(en)
|
2011-05-04 |
2020-09-15 |
Dhanapalan Nagarathnam |
Novel compounds as modulators of protein kinases
|
EP2520573A1
(en)
*
|
2011-05-06 |
2012-11-07 |
Westfälische Wilhelms-Universität Münster |
Compounds with matrix-metalloproteinase inhibitory activity
|
US9023318B2
(en)
|
2011-06-08 |
2015-05-05 |
Siemens Medical Solutions Usa, Inc. |
Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
RU2014111823A
(ru)
|
2011-08-29 |
2015-10-10 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения и их применения
|
JP5914667B2
(ja)
|
2011-09-22 |
2016-05-11 |
ファイザー・インク |
ピロロピリミジンおよびプリン誘導体
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
ES2654160T3
(es)
|
2011-10-04 |
2018-02-12 |
Igem Therapeutics Limited |
Anticuerpos de IgE anti-HMW-MAA
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
EP3345624A1
(en)
|
2012-02-22 |
2018-07-11 |
The Regents Of The University Of Colorado |
Bouvardin derivatives and therapeutic uses thereof
|
KR102164317B1
(ko)
|
2012-03-30 |
2020-10-13 |
리젠 파마슈티컬스 소시에떼 아노님 |
C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
ES2644758T3
(es)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
Moduladores de PKM2 y métodos para su uso
|
LT2914296T
(lt)
|
2012-11-01 |
2018-09-25 |
Infinity Pharmaceuticals, Inc. |
Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9999680B2
(en)
|
2013-02-28 |
2018-06-19 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
|
ES2738493T3
(es)
|
2013-03-14 |
2020-01-23 |
Tolero Pharmaceuticals Inc |
Inhibidores de JAK2 y ALK2 y métodos para su uso
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
CA2904393A1
(en)
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
AU2014273946B2
(en)
|
2013-05-30 |
2020-03-12 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3363800A1
(en)
|
2013-10-03 |
2018-08-22 |
Kura Oncology, Inc. |
Heterocyclic inhibitors of erk and methods of use
|
MY175778A
(en)
|
2013-10-04 |
2020-07-08 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
EP3636639A1
(en)
|
2013-10-10 |
2020-04-15 |
Araxes Pharma LLC |
Inhibitors of kras g12c
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
JP6574203B2
(ja)
|
2014-04-30 |
2019-09-11 |
ファイザー・インク |
シクロアルキル結合ジヘテロ環誘導体
|
AP2017009690A0
(en)
|
2014-06-19 |
2017-01-31 |
Ariad Pharma Inc |
Heteroaryl compounds for kinase inhibition
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
US10934360B2
(en)
|
2014-07-31 |
2021-03-02 |
The Hong Kong University Of Science And Technology |
Human monoclonal antibodies against EPHA4 and their use
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
WO2016172214A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
EP3288957A4
(en)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
|
KR102608921B1
(ko)
|
2015-05-18 |
2023-12-01 |
스미토모 파마 온콜로지, 인크. |
생체 이용률이 증가된 알보시딥 프로드러그
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
US10308660B2
(en)
*
|
2015-06-19 |
2019-06-04 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
AU2016355433C1
(en)
|
2015-11-16 |
2021-12-16 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
EA201891304A1
(ru)
|
2015-12-03 |
2019-01-31 |
Агиос Фармасьютикалс, Инк. |
ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CA3011455A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
PT3429591T
(pt)
|
2016-03-16 |
2023-06-21 |
Univ Michigan Regents |
Derivados de tieno[2,3-d]pirimidina substituídos como inibidores de menina-llm e métodos de utilização
|
TWI743096B
(zh)
|
2016-03-16 |
2021-10-21 |
美商庫拉腫瘤技術股份有限公司 |
Menin-mll之橋聯雙環抑制劑及使用方法
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
ES2910787T3
(es)
|
2016-05-12 |
2022-05-13 |
Univ Michigan Regents |
Inhibidores de ASH1L y métodos de tratamiento con los mismos
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
JP2019534260A
(ja)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤としての複素環式化合物およびその使用方法
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10132797B2
(en)
|
2016-12-19 |
2018-11-20 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
BR112019012976A2
(pt)
|
2016-12-22 |
2019-12-31 |
Amgen Inc |
inibidores de kras g12c e métodos de uso dos mesmos
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
CN110382483A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的n-杂环化合物及其使用方法
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液***恶性肿瘤和尤因肉瘤的方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
EP3684814A1
(en)
|
2017-09-18 |
2020-07-29 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
TW201920170A
(zh)
|
2017-09-20 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
經取代之menin-mll 抑制劑及使用方法
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
CN111655257A
(zh)
|
2017-11-10 |
2020-09-11 |
密歇根大学董事会 |
Ash1l抑制剂及用其进行治疗的方法
|
US11013741B1
(en)
|
2018-04-05 |
2021-05-25 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
EP3788053A1
(en)
|
2018-05-04 |
2021-03-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US11319302B2
(en)
|
2018-06-07 |
2022-05-03 |
The Regents Of The University Of Michigan |
PRC1 inhibitors and methods of treatment therewith
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
CA3103995A1
(en)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
US20210380595A1
(en)
|
2018-10-24 |
2021-12-09 |
Araxes Pharma Llc |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MA55136A
(fr)
|
2018-11-19 |
2022-02-23 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CA3120383A1
(en)
|
2018-11-29 |
2020-06-04 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
JOP20210154B1
(ar)
|
2018-12-20 |
2023-09-17 |
Amgen Inc |
مثبطات kif18a
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CR20210665A
(es)
|
2019-05-21 |
2022-01-25 |
Amgen Inc |
Formas en estado sólido
|
WO2021003417A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
JP2022542319A
(ja)
|
2019-08-02 |
2022-09-30 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
US20220281843A1
(en)
|
2019-08-02 |
2022-09-08 |
Amgen Inc. |
Kif18a inhibitors
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114391012A
(zh)
|
2019-08-02 |
2022-04-22 |
美国安进公司 |
作为kif18a抑制剂的吡啶衍生物
|
TW202126636A
(zh)
|
2019-09-30 |
2021-07-16 |
美商阿吉歐斯製藥公司 |
作為menin抑制劑之六氫吡啶化合物
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
AU2020372881A1
(en)
|
2019-10-28 |
2022-06-09 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS G12C mutant
|
CN115551500A
(zh)
|
2019-10-31 |
2022-12-30 |
大鹏药品工业株式会社 |
4-氨基丁-2-烯酰胺衍生物及其盐
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
AU2020379731A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN116425742A
(zh)
|
2019-11-08 |
2023-07-14 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
EP4087611A1
(en)
|
2020-01-07 |
2022-11-16 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
EP4114852A1
(en)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
EP4168002A1
(en)
|
2020-06-18 |
2023-04-26 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
TW202216151A
(zh)
|
2020-07-15 |
2022-05-01 |
日商大鵬藥品工業股份有限公司 |
含有使用於腫瘤之治療之嘧啶化合物之組合
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
KR20230170039A
(ko)
|
2021-04-13 |
2023-12-18 |
뉴베일런트, 아이엔씨. |
Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
US20230106174A1
(en)
|
2021-05-05 |
2023-04-06 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022250170A1
(en)
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023211812A1
(en)
|
2022-04-25 |
2023-11-02 |
Nested Therapeutics, Inc. |
Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024010925A2
(en)
|
2022-07-08 |
2024-01-11 |
Nested Therapeutics, Inc. |
Mitogen-activated protein kinase (mek) inhibitors
|